Russell Investments Group Ltd. Purchases 2,888 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Russell Investments Group Ltd. lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 9.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,671 shares of the company’s stock after acquiring an additional 2,888 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of Structure Therapeutics worth $940,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC increased its holdings in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the period. FNY Investment Advisers LLC bought a new position in Structure Therapeutics in the fourth quarter worth approximately $40,000. Assetmark Inc. lifted its holdings in Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock worth $62,000 after buying an additional 953 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Structure Therapeutics during the 4th quarter valued at $113,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several recent research reports. Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Up 6.2 %

NASDAQ:GPCR opened at $23.10 on Tuesday. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74. The company has a market cap of $1.32 billion, a PE ratio of -31.22 and a beta of -1.35. The company’s 50 day moving average is $20.21 and its two-hundred day moving average is $28.17.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.